A Randomized Phase III Study of Docetaxel/ Epirubicin Versus Tailored Regimens as Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 3 cm.

Trial Profile

A Randomized Phase III Study of Docetaxel/ Epirubicin Versus Tailored Regimens as Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 3 cm.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Epirubicin (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Vinorelbine
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TaiNAC
  • Most Recent Events

    • 21 Apr 2011 Planned end date changed from May 2011 to May 2013 as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
    • 12 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top